IP Library › Granted Patent US 8,563,607
Granted Patent B2
US 8,563,607 · App. 13/271,058 · Granted Oct 22, 2013

Polyphenol proteasome inhibitors, synthesis, and methods of use

Inventors: Q. Ping Dou (Grosse Pointe, MI); Tak-Hang Chan (Montreal, CA); David M. Smith (Boston, MA)
Assignees: University of South Florida; McGill University; The Hong Kong Polytechnic University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,607
App. No.
13/271,058
Granted
Oct 22, 2013
Kind
B2
Abstract

The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.

Claims (13)

1. A method for treating cancer comprising administering an effective amount of a compound or a composition comprising said compound to a patient wherein the compound has a formula of:

or a pharmaceutically acceptable salt, wherein said cancer is a prostate cancer or leukemia.

2. The method according to claim 1 , wherein said administering is conducted by a route selected from the group consisting of orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intraarterially, transdermally, and via a mucus membrane.

3. The method according to claim 1 , wherein said compound has less than 100% optical purity.

4. The method according to claim 1 , wherein said compound is optically pure.

5. The method according to claim 1 , wherein said compound is:

6. The method according to claim 1 , wherein said compound is:

7. The method according to claim 1 , wherein said compound is:

8. The method according to claim 1 , wherein said compound is:

9. The method according to claim 1 , wherein said compound is:

10. The method according to claim 1 , wherein said cancer is prostate cancer.

11. The method according to claim 1 , wherein the patient is a human.

12. The method according to claim 1 , wherein said cancer is leukemia.

Continuity (6)
Continuation 12660351 · Feb 25, 2010
Division 11820799 · Jun 20, 2007
Continuation 10764728 · Jan 26, 2004
Provisional Application 60442213 · Jan 24, 2003
Provisional Application 60443554 · Jan 30, 2003
Related Publication 20120029067A1 · Feb 2, 2012